Palvella Therapeutics, Inc. (NASDAQ: PVLA) announced the appointment of James Treat, M.D., as Chief Medical Officer, effective December 21, 2026.

Dr. Treat most recently served as a pediatric dermatologist and associate program director of the Pediatric Dermatology Fellowship Program at Children's Hospital of Philadelphia (CHOP). He also holds a position as Professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

In his new role, Dr. Treat will lead Palvella's medical organization and oversee clinical development, medical affairs, and scientific engagement. He previously served as a site investigator at CHOP for the company's Phase 3 SELVA and Phase 2 studies of QTORIN rapamycin in microcystic lymphatic malformations.

Dr. Treat is board-certified in both dermatology and pediatric dermatology and has published research on lymphatic malformations and PIK3CA-driven disease. He is a co-author of the 13th and 14th editions of Andrews' Diseases of the Skin: Clinical Dermatology.

He received the CHOP Master Clinician Award in 2013 and was elected to Penn Medicine's Academy of Master Clinicians in 2020. He has also received a Presidential Citation Award from the American Academy of Dermatology and was named the Pediatric Dermatology Research Alliance's 2023 Mentor of the Year.

Dr. Treat earned his B.A. and M.D. from the University of Pennsylvania and completed his dermatology residency at the Hospital of the University of Pennsylvania and a pediatric dermatology fellowship at CHOP.